Over the past decade, the UK has made bold investments in advanced therapy medicinal products (ATMPs), betting on homegrown innovation to lead the next frontier in medicine. Between public funding initiatives and strategic infrastructure developments such as the expansion of GMP cleanroom space and the establishment of centres including Catapult’s Stevenage manufacturing hub, the UK biotech landscape positioned itself as a hotbed for cell and gene therapy development.
Fast forward five years, and that investment has laid a powerful foundation. Yet, as the ecosystem matures, we’re seeing a noticeable shift. Rather than solely focusing on the development of proprietary therapies, the UK is experiencing a rise in platform companies, enabling technologies, and service-based models. It’s a strategic pivot from biotech companies racing to bring their own treatments to market, to a new generation of businesses solving the operational challenges that underpin successful ATMP delivery.
The rise of the enablers
Rather than announcing blockbuster clinical trials or new treatment modalities, these companies are tackling the bottlenecks that make commercialisation of ATMPs so difficult, such as challenges in scale, automation, quality assurance, and regulatory compliance. Their work is critical and increasingly recognised as such.
Why the shift?
In this environment, companies that offer the tools, technologies, and services to enable others stand on more stable ground. It’s the classic ‘picks and shovels’ model, supporting the gold rush, rather than participating directly in it. These businesses tend to have more predictable revenue, shorter product development cycles, and clearer paths to scale.
Reimagining UK infrastructure
While the UK continues to generate world-class scientific research and high-potential biotech innovations, it is increasingly distinguishing itself as a global centre for the development, scale-up, and commercialisation of advanced therapies. Rather than shifting away from innovation, the UK is complementing its academic strengths with a robust infrastructure for GMP manufacturing, regulatory excellence, and clinical trial delivery. This evolving role as a reliable hub for translating early-stage discoveries into scalable, compliant products makes the UK an essential part of the global biotech value chain, particularly in complex areas like cell and gene therapies, where manufacturing and quality oversight are as critical as the science itself.
Talent trends: What the shift means for hiring
It’s a different mindset. Employees must be flexible, commercially savvy, and deeply familiar with GMP standards and operational execution. Careers in biotech are no longer limited to roles in companies developing their own therapies; there is now strong demand across contract development and manufacturing organisations (CDMOs), technology providers, and service platforms.
This evolution opens up more diverse career pathways, but it also challenges hiring teams to rethink their ideal candidate profiles.
Evolution, not decline
For biotech employers, that means hiring differently. The value now lies in operational excellence, scalable systems, and the ability to bring complex therapies to life at scale. For candidates, it means exciting roles in engineering, regulatory affairs, automation, and quality assurance that are directly shaping the future of healthcare.
Partner with Blackfield Associates to hire for the next wave
“Platform biotech is where the UK is quietly excelling. Companies need people who can bridge the technical, regulatory, and operational gaps, and we’re helping them find that talent.”
Get in touch with us today to build your team and enable you to scale the next generation of ATMPs.
